Panel testing can identify women who are at increased risk for breast cancer. However, those at risk for triple-negative breast cancer cannot easily be identified because other than BRCA1, genes that increase the risk for triple-negative breast cancer are unknown. A new study uses panel testing to identify which genes increase the risk for triple-negative breast cancer. (8/23/18)
The following are studies enrolling people with early-stage, TNBC.
A number of other clinical trials for patients with early-stage TNBC can be found here.
Below are clinical trials that include genetic counseling and testing.
Other genetic counseling or testing studies may be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.